antimicrobial resistance. Bacterial DNA gyrase and topoisomerase IV are validated targets for the development of antibiotics. They can be inhibited at their catalytic sites or at their ATP binding sites. Here we present the design of new hybrids between the catalytic inhibitor ciprofloxacin and ATP-competitive inhibitors that show low nanomolar inhibition of DNA gyrase and antibacterial activity against
细菌酶的多目标
配体的发现是对抗快速传播的抗菌素耐药性的重要策略。细菌DNA促旋酶和拓扑异构酶IV是开发抗生素的有效靶标。它们可以在其催化位点或在其
ATP结合位点被抑制。在这里,我们介绍了催化
抑制剂环丙沙星和
ATP竞争性
抑制剂之间的新杂合体的设计,这些杂合体显示出对DNA促旋酶的低纳摩尔抑制作用和对革兰氏阴性病原体的抗菌活性。最有效的杂种3a对肺炎克雷伯菌的MIC为0.5 µg / mL ,对阴沟肠杆菌的MIC为4 µg / mL ,对大肠杆菌的MIC为2 µg / mL 。另外,抑制突变体大肠杆菌菌株显示这些杂合
抑制剂与DNA促旋酶的两个亚基(GyrA,GyrB)相互作用,并且与这两个位点的结合有助于它们的抗菌活性。